iRadimed (NASDAQ:IRMD) Releases Earnings Results, Beats Expectations By $0.02 EPS

iRadimed (NASDAQ:IRMD) posted its quarterly earnings results on Friday. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02, FiscalAI reports. The company had revenue of $20.47 million during the quarter, compared to the consensus estimate of $20.35 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed updated its FY 2026 guidance to 2.090-2.240 EPS and its Q3 2026 guidance to 0.540-0.590 EPS.

Here are the key takeaways from iRadimed’s conference call:

• Strong customer demand for the new 3870 pump drove bookings to more than double units shipped, with roughly 70% of replacement orders using four-channel quad systems and ASPs exceeding $110,000.
• IRadimed achieved its target of producing more than 130 3870 pumps in Q2 and plans to exceed 300 units in Q3, with startup costs expected to decline by more than 50% as manufacturing efficiencies improve.
• Q2 revenue was essentially flat year over year at $20.5 million, while gross margin fell to 74% from 78% and GAAP EPS declined to $0.41 from $0.45 due to the initial 3870 production ramp.
• Recurring revenue trends remained healthy, including 14% growth in disposables, while domestic patient-monitor sales reached a record 71 units and the company cited strong backlogs across pumps, monitors, and ferromagnetic detection systems.
• Management reaffirmed full-year 2026 guidance of $91 million–$96 million in revenue and $1.90–$2.05 in GAAP EPS, expects improving margins through the second half, and said a $100 million revenue run rate in Q4 is within reach.

iRadimed Price Performance

Shares of NASDAQ IRMD traded down $4.35 on Friday, hitting $90.86. The company’s stock had a trading volume of 308,080 shares, compared to its average volume of 111,471. iRadimed has a 12-month low of $57.83 and a 12-month high of $107.90. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of 49.65 and a beta of 0.90. The stock has a 50 day moving average of $94.54 and a 200-day moving average of $95.70.

iRadimed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 28th. Shareholders of record on Friday, August 14th will be given a dividend of $0.20 per share. The ex-dividend date is Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s payout ratio is presently 43.72%.

Analysts Set New Price Targets

Separately, Weiss Ratings cut iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $120.00.

Insider Activity

In related news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $87.51, for a total value of $437,550.00. Following the sale, the chief executive officer owned 2,175,000 shares of the company’s stock, valued at approximately $190,334,250. This represents a 0.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 21,250 shares of company stock worth $1,836,403. Insiders own 34.60% of the company’s stock.

Hedge Funds Weigh In On iRadimed

A number of institutional investors have recently made changes to their positions in the stock. Quarry LP purchased a new stake in shares of iRadimed in the third quarter valued at $40,000. Tower Research Capital LLC TRC increased its position in iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares in the last quarter. Virtus Advisers LLC acquired a new position in iRadimed in the 3rd quarter valued at about $117,000. Aquatic Capital Management LLC raised its stake in iRadimed by 210,400.0% in the 3rd quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider’s stock valued at $150,000 after purchasing an additional 2,104 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in iRadimed in the 3rd quarter valued at about $164,000. 92.34% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting iRadimed

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
• Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
• Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.